Chairman of the board
Thomas Eklund has an MBA from Stockholm School of Economics and works as an independent advisor, chairman and investor in Life Science companies. Advisor to Impilo AB and Patricia Industries AB ( Investor AB), Chairman in Sedana Medical AB and Mabtech AB and board member of Biotage AB, Boule Diagnostics AB and Swedencare AB.
Thomas has an extensive background from investments and development of Life Science companies as Head of Investor Growth Capital Europé, AAC Capital, Chairman of Swedish Orphan International, Calliditas, GHP Speciality Care and Biotage.
Simon graduated with a M.Sc. in Finance from the Stockholm School of Economics in 1999 – including a CEMS Master from the University of Cologne in 1999 – and with a M.D. from Uppsala University Medical School in 2004. Simon started his career at Goldman Sachs International in London (2001-2003), followed by Altor in 2003-2004 and then joined SEB Enskilda in Stockholm in 2004, with a focus on Nordic healthcare transactions.
In 2008, Simon joined mid-market private equity fund AAC Capital in Stockholm, where he became a Partner in 2011. At AAC, Simon served on the board of Viking, Envirotainer (chairman) and Loparex. In 2013, Simon joined Envirotainer as CEO, a role he held until late 2016.
Magnus is Impilo’s responsible partner for Immedica and has 12 years of active ownership and governance experience within private equity and healthcare. Prior to joining Impilo in 2017, Magnus worked for Altor Equity Partners between 2009 and 2017 and for the Boston Consulting Group between 2004 and 2009. Magnus currently also serves on the Board of Directors for NutraQ and has previously served on the Boards of Orchid Orthopedics and Rossignol.